title: Migraine in the triptan era: progresses achieved, lessons learned and future developments.
abstract: Triptans, serotonin 5-HT1B/1D receptor agonists, more than revolutionizing the treatment of migraine, stimulated also ground breaking research that provided insights into the anatomy, physiology, and molecular pharmacology of migraine. This knowledge, in turn, is stimulating research on new mechanisms of action for the treatment of migraine. Accordingly, it is opportune to critically review the main advances in migraine science that happened in the triptan era. Herein we first review and conceptualize some of the progresses achieved in migraine science during the triptan era. We then review the class of the triptans--mechanism of action and clinical evidence. We close by briefly discussing the class of CGRP receptor antagonists, which is currently being developed for the acute treatment of migraine.
authors.affiliation: Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA. marcelo_bigal@merck.com
authors.forename: Marcelo E
authors.initials: ME
authors.lastname: Bigal
authors.forename: Abouch V
authors.initials: AV
authors.lastname: Krymchantowski
authors.forename: Tony
authors.initials: T
authors.lastname: Ho
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D017366:Serotonin Receptor Agonists; D014363:Tryptamines